Search PubMed⌕ Search

Biomedical subjects

Zelalem Temesgen

Publications and source records attributed to Zelalem Temesgen.

14 recordsLinked to original sources
PubMed2006

Comprehensive Health Enhancement Support System (CHESS) for people with HIV infection.

We investigated the utility and the pattern of use of the Comprehensive Health Enhancement Support System (CHESS), an Internet based consumer health informatics system for people living with HIV/AIDS. Eight patients utilized CHESS for 4 months. The total number of log-ins ranged between 1 and 93 (median 21), with a median of 4.6 per month (0.2-21.8). Discussions Group was the service most frequently accessed; the Referral Directory and Fat Assessment services were requested the least. The barriers to using CHESS were difficulty in using the laptop, being too busy, and the discussion group size being too small. Most participants agreed that CHESS was easy to use and helped them cope with and understand more about their disease. They also felt comfortable asking questions and felt more involved in their health care.

Adolescent↗
PubMed2006

Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults.

Despite dramatic declines in HIV-associated morbidity and mortality as a result of highly active antiretroviral therapy, management of heavily treatment-experienced patients remains complex and challenging. Treatment response rates with subsequent antiretroviral regimens are lower than with initial antiretroviral therapy. Additionally, increased mortality has been associated with multidrug-resistant HIV. We review data relevant to management of such patients and offer a systematic approach to constructing a salvage antiretroviral regimen.

Antiretroviral Therapy, Highly Active↗
PubMed2006

Rhino-orbitocerebral mucormycosis caused by Apophysomyces elegans.

Rhino-orbitocerebral mucormycosis (ROCM) caused by more common zygomycetes (e.g., Mucor) is known to cause rapidly fatal infections in immunocompromised patients. Apophysomyces elegans is an emerging zygomycete that has been reported to cause invasive cutaneous and rhino-orbitocerebral infections in immunocompetent individuals. Limited data exist describing the syndrome of ROCM caused by A. elegans. We describe a recent case and performed a comprehensive literature review to delineate the clinical characteristics of ROCM caused by A. elegans. Our case is a 50-year-old man with diabetes mellitus who presented with facial pain and right eye proptosis. Endoscopic sinus sampling revealed A. elegans. He was treated with liposomal amphotericin B and multiple debridements, with no disease on 1.5-year follow-up examination. Seven cases were identified on literature review, including the present case. Most patients (86%) were male, with a mean age of 40 years. Most patients (71%) did not have predisposing medical conditions. Three patients had predisposing head trauma. All presented with facial and/or periorbital pain. All had magnetic resonance imaging or computed tomography of the head showing intraorbital and/or sinus inflammation. Diagnosis was confirmed by histopathology and deep tissue culture in all cases. All patients required eye exenteration and extensive surgical debridement, in addition to intravenous amphotericin B. Six of the seven patients (86%) recovered. ROCM caused by A. elegans is rarely reported in the literature. Most such infections occurred in immunocompetent patients, often after facial trauma. Survival in ROCM caused by A. elegans is favorable in reported cases, with prompt surgical debridement and antifungal therapy.

Adult↗
PubMed2006

Current status of antiretroviral therapy.

At present, there are 22 FDA-approved antiretroviral agents, which are categorised into four classes of drugs. Several others are in various stages of basic and clinical development. The authors of this paper review the general characteristics of each class of antiretrovirals, as well as individual investigational agents that are in advanced clinical development. A brief synopsis of US and WHO antiretroviral treatment guidelines is also provided.

Antiretroviral Therapy, Highly Active↗
PubMed2006

Human immunodeficiency virus-associated peripheral neuropathies.

Peripheral neuropathy has emerged as the most common neurologic complication of human immunodeficiency virus (HIV) infection. It will continue to play an Important role in HIV Infection given the fact that HIV-infected Individuals are living longer, are at risk of long-term metabolic complications, and face an Increasing exposure to potentially neurotoxic antiretroviral drugs. We review the various types of peripheral neuropathy that have been associated with HIV infection, including distal symmetrical polyneuropathy, toxic neuropathy from antiretroviral drugs, diffuse infiltrative lymphocytosis syndrome, inflammatory demyelinating polyneuropathies, multifocal mononeuropathies, and progressive polyradiculopathy.

Antiretroviral Therapy, Highly Active↗
PubMed2005

Tipranavir.

Tipranavir is a newly approved protease inhibitor that belongs to the class of 4-hydroxy-5,6-dyhydro-2-pyrones. It exhibits potent in vitro activity against both human immunodeficiency virus (HIV)-1 and HIV-2, including clinical isolates with multiple protease inhibitor-resistant mutations. Tipranavir requires coadministration with ritonavir to achieve clinically meaningful serum concentration. In randomized, phase III, open-label trials, it was found to be superior to the currently available boosted protease inhibitors in highly treatment-experienced patients with multiple protease inhibitor mutations. Thus, it provides a welcome new option for salvage antiretroviral therapy. The most common adverse effects associated with tipranavir are diarrhea, nausea and vomiting. Common laboratory abnormalities include elevations of total cholesterol, triglycerides and liver enzymes.

Clinical Trials as Topic↗
PubMed2004

HIV and drug allergy.

Twenty individual antiretroviral drugs and two coformulation products are approved by the US Food and Drug Administration for the treatment of HIV-infected individuals. Many of these drugs have been associated with allergic/hypersensitivity reactions to varying degrees. The antiretroviral drugs that are most commonly associated with these types of reactions are abacavir, all of the nonnucleoside reverse transcriptase inhibitors, and amprenavir. Trimethoprim-sulfamethoxazole, although not an antiretroviral drug, is extensively used for the treatment and prophylaxis of HIV-related opportunistic infections and has been associated with a significant rate of adverse reactions. The authors provide an overview of these drug-related reactions and discuss their pathogenesis and management.

Antiviral Agents↗
PubMed2004

Initial antiretroviral therapy in chronically-infected HIV-positive adults.

Currently, there are 20 individual antiretroviral drugs and two co-formulation products that are approved by the FDA for the treatment of HIV-infected individuals. It is widely accepted that the selection of an appropriate first-line regimen is critical in assuring durable treatment response. This article reviews the factors that should be considered in the selection of an initial antiretroviral regimen and present the currently available evidence regarding the status of individual antiretroviral agents and treatment strategies relative to these factors.

Adult↗
PubMed2003

Osteoarticular infection complicating enterococcal endocarditis.

Despite the common occurrence of musculoskeletal complaints in patients with infective endocarditis, infectious osteoarticular complications are diagnosed infrequently. Moreover, although enterococcal infection is the third most common cause of infective endocarditis, infectious osteoarticular complications are rare. We report a case of disk space infection in a patient with enterococcal endocarditis. Blood cultures and an L3-4 aspirate grew Enterococcus faecalis, and transthoracic echocardiography revealed a large vegetation on the posterior mitral valve leaflet. The osteoarticular infection resolved with antimicrobial treatment, but worsening heart failure necessitated valve replacement surgery. The patient had an uneventful recovery with no evidence of recurrence or complications. A review of the medical literature from 1966 through 1998 identified 13 additional cases, only 8 of which provided clinical and treatment data. We present the clinical and laboratory findings reported in these cases, along with data from our patient. This report highlights the rare occurrence of osteoarticular infection in the setting of enterococcal endocarditis and emphasizes early recognition and treatment.

Anti-Bacterial Agents↗
PubMed2003

SARS: epidemiology, clinical presentation, management, and infection control measures.

Severe acute respiratory syndrome (SARS) is a recently recognized febrile respiratory illness that first appeared in southern China in November 2002, has since spread to several countries, and has resulted in more than 8000 cases and more than 750 deaths. The disease has been etiologically linked to a novel coronavirus that has been named the SARS-associated coronavirus. It appears to be spread primarily by large droplet transmission. There is no specific therapy, and management consists of supportive care. This article summarizes currently available information regarding the epidemiology, clinical features, etiologic agent, and modes of transmission of the disease, as well as infection control measures appropriate to contain SARS.

Animals↗